These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30008379)

  • 1. Determination of chidamide in rat plasma and cerebrospinal fluid.
    Yang H; Li C; Chen Z; Mou H; Gu L
    Regul Toxicol Pharmacol; 2018 Oct; 98():24-30. PubMed ID: 30008379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
    Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study.
    Wang X; Chen M; Wen C; Zhang Q; Ma J
    Biomed Chromatogr; 2013 Dec; 27(12):1801-6. PubMed ID: 23857175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chidamide tablets: HDAC inhibition to treat lymphoma.
    Xu Y; Zhang P; Liu Y
    Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
    Suresh PS; Devaraj VC; Srinivas NR; Mullangi R
    Biomed Chromatogr; 2017 Jan; 31(1):. PubMed ID: 27511598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
    Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
    Front Immunol; 2022; 13():835103. PubMed ID: 35185926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
    Ma J; Zhang Q; Wang X
    Xenobiotica; 2014 Sep; 44(9):849-54. PubMed ID: 24588344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
    Li YY; Wang YF; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
    Dong M; Ning ZQ; Xing PY; Xu JL; Cao HX; Dou GF; Meng ZY; Shi YK; Lu XP; Feng FY
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1413-22. PubMed ID: 22362161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
    Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
    Gao S; Li X; Zang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
    Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
    Zhang Q; Lu B; Li J
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3162-3166. PubMed ID: 28532668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells.
    Zhang W; Shen H; Zhang Y; Wang W; Hu S; Zou D; Zhou D
    Cancer Med; 2019 May; 8(5):2104-2113. PubMed ID: 30969023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
    He J; Chen Q; Gu H; Chen J; Zhang E; Guo X; Huang X; Yan H; He D; Yang Y; Zhao Y; Wang G; He H; Yi Q; Cai Z
    Haematologica; 2018 Aug; 103(8):1369-1379. PubMed ID: 29773595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines.
    Lin SH; Wang BY; Lin CH; Chien PJ; Wu YF; Ko JL; Chen JJ
    Mol Biol Rep; 2016 Jul; 43(7):687-95. PubMed ID: 27188428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.